383 related articles for article (PubMed ID: 31698143)
1. Cytochrome P450 derived epoxidized fatty acids as a therapeutic tool against neuroinflammatory diseases.
Atone J; Wagner K; Hashimoto K; Hammock BD
Prostaglandins Other Lipid Mediat; 2020 Apr; 147():106385. PubMed ID: 31698143
[TBL] [Abstract][Full Text] [Related]
2. Humble beginnings with big goals: Small molecule soluble epoxide hydrolase inhibitors for treating CNS disorders.
Zarriello S; Tuazon JP; Corey S; Schimmel S; Rajani M; Gorsky A; Incontri D; Hammock BD; Borlongan CV
Prog Neurobiol; 2019 Jan; 172():23-39. PubMed ID: 30447256
[TBL] [Abstract][Full Text] [Related]
3. Soluble Epoxide Hydrolase Inhibition to Face Neuroinflammation in Parkinson's Disease: A New Therapeutic Strategy.
Pallàs M; Vázquez S; Sanfeliu C; Galdeano C; Griñán-Ferré C
Biomolecules; 2020 May; 10(5):. PubMed ID: 32369955
[TBL] [Abstract][Full Text] [Related]
4. Soluble epoxide hydrolase as a therapeutic target for pain, inflammatory and neurodegenerative diseases.
Wagner KM; McReynolds CB; Schmidt WK; Hammock BD
Pharmacol Ther; 2017 Dec; 180():62-76. PubMed ID: 28642117
[TBL] [Abstract][Full Text] [Related]
5. Lipid mediators generated by the cytochrome P450-Epoxide hydrolase pathway.
Frömel T; Hu J; Fleming I
Adv Pharmacol; 2023; 97():327-373. PubMed ID: 37236763
[TBL] [Abstract][Full Text] [Related]
6. Relative Importance of Soluble and Microsomal Epoxide Hydrolases for the Hydrolysis of Epoxy-Fatty Acids in Human Tissues.
Morisseau C; Kodani SD; Kamita SG; Yang J; Lee KSS; Hammock BD
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34066758
[TBL] [Abstract][Full Text] [Related]
7. Role of epoxy-fatty acids and epoxide hydrolases in the pathology of neuro-inflammation.
Kodani SD; Morisseau C
Biochimie; 2019 Apr; 159():59-65. PubMed ID: 30716359
[TBL] [Abstract][Full Text] [Related]
8. Soluble Epoxide Hydrolase as a Therapeutic Target for Neuropsychiatric Disorders.
Shan J; Hashimoto K
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563342
[TBL] [Abstract][Full Text] [Related]
9. Soluble epoxide hydrolase: gene structure, expression and deletion.
Harris TR; Hammock BD
Gene; 2013 Sep; 526(2):61-74. PubMed ID: 23701967
[TBL] [Abstract][Full Text] [Related]
10. Determinants of Meal-Induced Changes in Circulating FFA Epoxides, Diols, and Diol-to-Epoxide Ratios as Indices of Soluble Epoxide Hydrolase Activity.
Oh YT; Yang J; Stefanovski D; Hammock B; Youn JH
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139180
[TBL] [Abstract][Full Text] [Related]
11. Increased epoxyeicosatrienoic acids and reduced soluble epoxide hydrolase expression in the preeclamptic placenta.
Dalle Vedove F; Fava C; Jiang H; Zanconato G; Quilley J; Brunelli M; Guglielmi V; Vattemi G; Minuz P
J Hypertens; 2016 Jul; 34(7):1364-70. PubMed ID: 27115337
[TBL] [Abstract][Full Text] [Related]
12. Modulation of mitochondrial dysfunction and endoplasmic reticulum stress are key mechanisms for the wide-ranging actions of epoxy fatty acids and soluble epoxide hydrolase inhibitors.
Inceoglu B; Bettaieb A; Haj FG; Gomes AV; Hammock BD
Prostaglandins Other Lipid Mediat; 2017 Nov; 133():68-78. PubMed ID: 28847566
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of soluble epoxide hydrolase ameliorates hyperhomocysteinemia-induced hepatic steatosis by enhancing β-oxidation of fatty acid in mice.
Yao L; Cao B; Cheng Q; Cai W; Ye C; Liang J; Liu W; Tan L; Yan M; Li B; He J; Hwang SH; Zhang X; Wang C; Ai D; Hammock BD; Zhu Y
Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G527-G538. PubMed ID: 30789748
[TBL] [Abstract][Full Text] [Related]
14. Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health.
Morisseau C; Hammock BD
Annu Rev Pharmacol Toxicol; 2013; 53():37-58. PubMed ID: 23020295
[TBL] [Abstract][Full Text] [Related]
15. Epoxyeicosatrienoic acids and soluble epoxide hydrolase in physiology and diseases of the central nervous system.
Kuo YM; Lee YH
Chin J Physiol; 2022; 65(1):1-11. PubMed ID: 35229747
[TBL] [Abstract][Full Text] [Related]
16. Omeprazole increases the efficacy of a soluble epoxide hydrolase inhibitor in a PGE₂ induced pain model.
Goswami SK; Inceoglu B; Yang J; Wan D; Kodani SD; da Silva CA; Morisseau C; Hammock BD
Toxicol Appl Pharmacol; 2015 Dec; 289(3):419-27. PubMed ID: 26522832
[TBL] [Abstract][Full Text] [Related]
17. Reno-protective mechanisms of epoxyeicosatrienoic acids in cardiovascular disease.
Elmarakby AA
Am J Physiol Regul Integr Comp Physiol; 2012 Feb; 302(3):R321-30. PubMed ID: 22116511
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of soluble epoxide hydrolase modulates inflammation and autophagy in obese adipose tissue and liver: role for omega-3 epoxides.
López-Vicario C; Alcaraz-Quiles J; García-Alonso V; Rius B; Hwang SH; Titos E; Lopategi A; Hammock BD; Arroyo V; Clària J
Proc Natl Acad Sci U S A; 2015 Jan; 112(2):536-41. PubMed ID: 25550510
[TBL] [Abstract][Full Text] [Related]
19. Cardiomyocyte-specific disruption of soluble epoxide hydrolase limits inflammation to preserve cardiac function.
Sosnowski DK; Jamieson KL; Gruzdev A; Li Y; Valencia R; Yousef A; Kassiri Z; Zeldin DC; Seubert JM
Am J Physiol Heart Circ Physiol; 2022 Oct; 323(4):H670-H687. PubMed ID: 35985007
[TBL] [Abstract][Full Text] [Related]
20. Targeting epoxides for organ damage in hypertension.
Imig JD
J Cardiovasc Pharmacol; 2010 Oct; 56(4):329-35. PubMed ID: 20531214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
